3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
42
Phase 3
12
Phase 1/2
11
Phase 1
11
Phase EARLY_PHASE1
2
Phase 2/3
2
Phase 4
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Sarcoma
1
Conditions
Ovarian Carcinosarcoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Interventions
Cisplatin
30
Magnetic Resonance Spectroscopy
23
Carboplatin
23
pembrolizumab
21
Paclitaxel
20
Gemcitabine
19
Specimen Handling
16
Drug Therapy
15
Dexamethasone
15
Radiotherapy
14
Nivolumab
14
Doxorubicin
14
Bevacizumab
14
atezolizumab
13
Oxaliplatin
13
Cyclophosphamide
13
Radiation
11
Pemetrexed
11
Cytarabine
11
Vincristine
10
Prednisone
10
Docetaxel
10
Capecitabine
10
venetoclax
9
Trastuzumab
9
Temozolomide
8
Rituximab
8
Platinum
8
Ipilimumab
8
Fluorouracil
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
niraparib
×
1 year
×
Clear all
NCT03651206
2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3
Recruiting
138 enrolled
NCT04159155
2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3
Terminated
11 enrolled